Table 1.
Patient characteristics.
| Female sex, N (%) | 81 (100%) |
| Age in years, median (IQR) | 63.2 (56.2, 68.4) |
| Prior number of systemic therapies, median (IQR) | 4 (3, 6) |
| Prior therapy exposure | |
| Prior platinum-based therapy | 81 (100%) |
| Prior PARP inhibitor | 47 (58.0%) |
| ECOG performance status at start of trial, N (%) | |
| 0 | 15 (18.5%) |
| 1 | 66 (81.5%) |
| FIGO stage at diagnosis, N (%) | |
| I or II | 3 (3.70%) |
| III | 60 (74.1%) |
| IV | 18 (22.2%) |
| Race, N (%) | |
| African American/Black | 5 (6.17%) |
| Asian | 2 (2.47%) |
| White | 73 (90.1%) |
| Unknown | 1 (1.23%) |
| BRCA mutation status, N (%) | |
| BRCA-mutant | 18 (22.2%) |
| BRCA-wildtype | 63 (77.8%) |
| Platinum sensitivity, N (%) | |
| Platinum-sensitive | 13 (16.0%) |
| Platinum-resistant | 67 (82.7%) |
| Platinum-refractory | 1 (1.23%) |
| Baseline CA125, median (IQR) | 349 (107, 1500)* |
| Baseline CA125, N (%) | |
| Normal (0–16.3 units/mL) | 3 (3.70%) |
| Abnormal (> 16.3 units/mL) | 78 (96.3%) |
ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, IQR interquartile range, RECIST response evaluation criteria in solid tumors. *Values > 1500 units/mL calculated as 1500 units/mL.